Windlas Biotech (NSE:WINDLAS) Cash-to-Debt : 56.56 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Windlas Biotech Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Windlas Biotech's cash to debt ratio for the quarter that ended in Mar. 2024 was 56.56.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Windlas Biotech could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Windlas Biotech's Cash-to-Debt or its related term are showing as below:

NSE:WINDLAS' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.07 Med: 13.92 Max: 56.56
Current: 56.56

During the past 6 years, Windlas Biotech's highest Cash to Debt Ratio was 56.56. The lowest was 1.07. And the median was 13.92.

NSE:WINDLAS's Cash-to-Debt is ranked better than
86.52% of 1046 companies
in the Drug Manufacturers industry
Industry Median: 0.93 vs NSE:WINDLAS: 56.56

Windlas Biotech Cash-to-Debt Historical Data

The historical data trend for Windlas Biotech's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Windlas Biotech Cash-to-Debt Chart

Windlas Biotech Annual Data

Trend

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Cash-to-Debt

Get a 7-Day Free Trial

1.41

1.68

26.91

26.17

56.56

Windlas Biotech Quarterly Data
	Mar19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial												26.17	N/A	27.06	N/A	56.56

Competitive Comparison of Windlas Biotech's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Windlas Biotech's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Windlas Biotech's Cash-to-Debt falls into.

Windlas Biotech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Windlas Biotech's Cash to Debt Ratio for the fiscal year that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2059.15	/	(16.23	+	20.18)
	=	56.55

Windlas Biotech's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2059.15	/	(16.23	+	20.18)
	=	56.55

Windlas Biotech (NSE:WINDLAS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Windlas Biotech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Windlas Biotech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Windlas Biotech (NSE:WINDLAS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Windlas Biotech Ltd (NSE:WINDLAS) » Definitions » Cash-to-Debt

Traded in Other Exchanges

543329:India

Address

Golf Course Extension Road, 705-706, Vatika Professional Point, Sector-66, Gurgaon, HR, IND, 122 001

Website

https://www.windlas.com

Windlas Biotech Ltd is a pharmaceutical formulations contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.

Windlas Biotech (NSE:WINDLAS) Headlines

No Headlines